Introduction
EVO ICL — short for EVO Implantable Collamer Lens — is a surgeon-implanted lens placed inside the eye to correct refractive errors including myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. Unlike LASIK and PRK, which permanently reshape the cornea, EVO ICL works by adding a precisely manufactured lens between the eye’s natural lens and the iris, leaving the corneal tissue entirely intact.
The procedure has gained significant traction among patients who are not LASIK candidates due to thin corneas, high prescriptions, or chronic dry eye. It has also attracted patients who are technically eligible for laser vision correction but prefer a reversible, additive approach.
For consumers researching vision correction options, understanding what EVO ICL is — and how it differs mechanically from laser procedures — is the foundation for every subsequent decision. This page provides a thorough, clinically accurate overview of the technology, the science behind it, and why it has earned recognition among the eye care community.
To see which surgeons have demonstrated exceptional outcomes with this procedure, visit the EVO ICL Awards hub.
Section 1: The Technology Behind EVO ICL
What Is Collamer?
The lens material used in EVO ICL is called Collamer, a proprietary biocompatible polymer developed by STAAR Surgical. Collamer is a collagen co-polymer, meaning it is partially derived from collagen — the same structural protein found in the human eye. This composition is central to the lens’s clinical performance. The eye does not recognize Collamer as a foreign substance, which dramatically reduces the inflammatory response that can occur with other implanted materials.
Collamer also has a naturally high water content, which contributes to its optical clarity and makes it mechanically soft and flexible. This flexibility is what allows the lens — which, when fully unfolded, measures between 12.1 and 13.7 millimeters in diameter depending on the patient’s eye size — to be folded, inserted through a micro-incision of approximately 3 millimeters, and then unfold inside the eye.
The EVO Generation and Its Central Port
The “EVO” designation refers to the current generation of the Visian ICL platform. The defining advancement of EVO ICL over earlier versions is the central aqueous port — a 360-micrometer hole in the center of the lens. This small opening allows aqueous humor (the fluid that normally circulates inside the front chamber of the eye) to flow freely around and through the lens without restriction.
In previous generations of ICL, a separate surgical step called a laser peripheral iridotomy (LPI) was required before lens implantation. The LPI created a small hole in the iris to prevent fluid from becoming trapped, a condition called pupillary block that could raise intraocular pressure dangerously. The central port on EVO ICL eliminates the need for this pre-treatment step, simplifying the patient’s experience and reducing pre-operative preparation time.
How the Lens Corrects Vision
The EVO ICL sits in what is called the posterior chamber — the space directly behind the iris and in front of the eye’s natural crystalline lens. From this position, it acts as a high-powered optical element in the visual system. Light entering the eye passes through the cornea, through the pupil, and then through the ICL before reaching the natural lens and ultimately the retina.
For myopic patients, the ICL is concave (curved inward) and diverges incoming light rays so they converge at the correct focal point on the retina rather than in front of it. For hyperopic patients, the lens is convex. Toric versions of the ICL include additional optical power in a specific meridian to counteract the irregular corneal curvature of astigmatism.
The lens is custom manufactured for each patient based on detailed pre-operative measurements of their eye, including axial length, anterior chamber depth, white-to-white distance (the horizontal diameter of the cornea), and manifest refraction (the patient’s measured prescription).
FDA Approval and Regulatory History
EVO ICL received FDA approval in the United States in March 2022, covering the treatment of myopia ranging from -3.00 to -20.00 diopters, with or without astigmatism. However, the technology had been available internationally for more than two decades before U.S. approval. Clinical data from European, Asian, and Latin American markets contributed substantially to the safety and efficacy evidence reviewed by the FDA.
STAAR Surgical reports that more than two million EVO ICL procedures have been performed worldwide. This global track record is a significant factor in the confidence that both surgeons and patients bring to the procedure.
Section 2: The Patient Experience — From Consultation to Clear Vision
Pre-Operative Evaluation
Before a patient can be considered for EVO ICL, a comprehensive eye exam is required. This evaluation typically includes:
- Manifest and cycloplegic refraction to accurately measure the patient’s prescription
- Corneal topography to map the curvature and thickness of the cornea
- Anterior segment OCT (optical coherence tomography) to measure the depth of the anterior chamber and the relationship between anatomical structures
- Specular microscopy to assess endothelial cell density — the health of the cells lining the back of the cornea
- Dilated fundus examination to evaluate the retina, particularly important in highly myopic eyes that carry a higher baseline risk of retinal issues
Surgeons experienced in EVO ICL use these measurements to calculate the appropriate lens size and power. Getting the sizing correct is critical — a lens that is too large can cause elevated intraocular pressure or contact the natural lens; a lens that is too small may rotate or vault too shallowly and contact the iris.
The Implantation Procedure
The surgery itself typically takes 20 to 30 minutes per eye and is performed under topical anesthesia (eye drops), meaning no injections and no general anesthesia for most patients. The surgeon creates a small corneal incision, introduces viscoelastic fluid to protect intraocular structures, folds and inserts the lens using a specialized injector, positions the lens haptics (the arms that support the lens) behind the iris, and removes the viscoelastic material. The incision is self-sealing and typically requires no sutures.
Immediate Post-Operative Period
Most patients experience dramatic visual improvement within hours of surgery. Some report noticing sharper vision before leaving the surgical suite. Mild light sensitivity, haloes, and scratchiness are common in the first 24 to 48 hours and resolve quickly for the majority of patients.
Section 3: How Top EVO ICL Surgeons Approach the Technology
Precision in Sizing and Vaulting
Among the most important technical skills an EVO ICL surgeon develops is the ability to accurately size the lens for each individual patient. Vault — the space between the back surface of the ICL and the front surface of the natural lens — is a key outcome metric. Target vault is typically between 250 and 750 microns. Too little vault and the natural lens is at risk; too much vault and aqueous flow can be obstructed.
Surgeons recognized by the EVO ICL Awards consistently demonstrate precise vault outcomes, minimal intraocular pressure variation, and low rates of lens exchange.
Staying Current With Clinical Evidence
The best EVO ICL surgeons are active participants in the ongoing research community. They present at meetings such as the American Society of Cataract and Refractive Surgery (ASCRS) and the European Society of Cataract and Refractive Surgeons (ESCRS), contribute to peer-reviewed journals, and adopt protocol refinements as the evidence base evolves.
Customized Patient Selection
Outstanding surgeons do not implant EVO ICL in every patient who requests it. They apply rigorous candidacy criteria and, when a patient is borderline, may recommend a different procedure or additional evaluation before proceeding. This commitment to appropriate patient selection is a hallmark of surgical excellence.
For related reading on surgeon evaluation standards, see How EVO ICL Surgeons Are Evaluated for Awards.
Section 4: What Patients Should Look For
When researching EVO ICL providers, patients benefit from focusing on a specific set of qualifications and practice characteristics:
Surgical volume. EVO ICL implantation requires specialized training and practice. Surgeons who perform the procedure regularly develop the tactile proficiency and pattern recognition that contribute to consistent outcomes. Ask how many EVO ICL procedures the surgeon performs annually and in total.
Comprehensive diagnostic equipment. A practice that invests in anterior segment OCT, modern topography platforms, and specular microscopy is demonstrating a commitment to thorough pre-operative evaluation. These tools are not optional for safe EVO ICL practice — they are foundational.
Transparent outcomes data. The most trustworthy practices can speak to their own outcome statistics, including average vault, uncorrected visual acuity results, and complication rates. Ask for this information directly.
Post-operative follow-up protocols. EVO ICL patients require careful monitoring of intraocular pressure and vault in the weeks and months following surgery. A practice with structured follow-up care is a safer choice.
For more on what distinguishes the most qualified practitioners, see EVO ICL Surgeon Credentials: What to Look For.
Frequently Asked Questions
Is EVO ICL permanent? EVO ICL is designed to remain in the eye permanently, but unlike corneal reshaping procedures, it can be surgically removed if circumstances change. This reversibility is one of its most frequently cited advantages. For a full discussion, see The Reversibility Advantage of EVO ICL.
Who is not a candidate for EVO ICL? Patients with insufficient anterior chamber depth, low endothelial cell count, uncontrolled glaucoma, or certain autoimmune conditions are generally not candidates. A full candidacy discussion is available at EVO ICL Candidacy: Who Is a Good Candidate?.
How does EVO ICL compare to LASIK in terms of outcomes? Both procedures produce excellent visual outcomes for appropriate patients. EVO ICL offers advantages for patients with high prescriptions or thin corneas. A detailed comparison is available at EVO ICL vs LASIK: Which Vision Correction Is Right for You?.
Does the EVO ICL lens block UV light? Yes. Collamer material inherently filters UV-A and UV-B radiation, providing a layer of protection for the retina. See EVO ICL and UV Protection: Built-In Eye Health Benefits for details.
How much does EVO ICL cost? Pricing varies by practice, geographic market, and the complexity of the prescription. See EVO ICL Cost: Pricing, Financing, and Value for a full breakdown.
Next Steps
Understanding what EVO ICL is and how it works is the first step toward making a confident decision about vision correction. The next step is finding a surgeon whose training, experience, and outcomes meet the standards you deserve.
The EVO ICL Awards program identifies surgeons who consistently deliver excellent results with this technology. Use this resource to begin your search, and explore the related pages in this hub to continue building your knowledge before your consultation.